Fractional Business Development for CROs and CDMOs
Running a CRO or CDMO without a dedicated BD person means your pipeline is inconsistent, your prospecting is reactive, and your growth depends on referrals you can't control. Hiring a full-time VP of Business Development solves the problem but costs $150,000 to $200,000 per year before benefits, equity, and onboarding time.
Fractional business development is a third option: senior BD expertise, applied to your specific pipeline challenges, without the full-time cost or commitment.
What Is Fractional Business Development in Life Sciences?
Fractional business development means working with an experienced BD professional on a part-time or project basis. You get the strategy, the outreach, and the market expertise of a senior BD director, at a fraction of the cost of a full-time hire.
This is not the same as hiring a generalist freelancer. A fractional BD consultant for life sciences needs to understand how pharma sponsors evaluate CRO partners, what goes into a credible RFP response, and why a 12-month sales cycle is normal for first-time CDMO engagements. These are not skills a generalist agency can replicate.
It is also not the same as a lead generation agency. Lead generation delivers contact lists. Fractional BD delivers pipeline strategy, relationship development, and market positioning, the work that converts contacts into qualified conversations.
When Does a Small CRO or CDMO Need Fractional BD?
You have no dedicated BD person
Your scientific team is excellent. Your delivery track record is strong. But no one is consistently prospecting, following up, or building the market relationships that lead to new contracts. Business development happens in between everything else, which means it rarely happens.
Your pipeline is inconsistent
You close projects, then spend weeks finding the next one. The feast-and-famine cycle is the most common growth problem for small CROs and CDMOs, and it comes from inconsistent BD effort, not from lack of capabilities.
You want to enter the US or UK market
Breaking into a new geography requires local market knowledge: who the active sponsors are, which conferences matter, how procurement decisions are made in that market. Getting this wrong is expensive. Getting it right with a guide is faster.
You need senior BD expertise without a $150K+ annual commitment
A fractional model lets you access the level of BD expertise your business needs now, scale it up or down as your pipeline evolves, and keep your fixed cost base manageable while you grow.
What Fractional BD with Corstrate Includes
Corstrate works with small CROs, CDMOs, regulatory consultancies, PV companies, data management and medical writing firms, and other life sciences service providers. The scope adapts to what your business actually needs.
BD strategy and ICP definition
Before any outreach, the work starts with clarity: who is your ideal client, what problems do you solve better than anyone else, and what does your competitive position look like in your target geography. A clear ICP makes every subsequent BD activity more efficient.
Prospect research and buying signals analysis
Identifying the right prospect at the right moment is what separates effective BD from cold email volume. Buying signals in the life sciences context include new clinical trial registrations, biotech funding rounds, sponsor hiring patterns, and therapeutic pipeline developments that indicate an upcoming outsourcing need. These signals require scientific literacy to interpret. A general marketing team will miss them.
Outreach and pipeline management
Structured outreach using your existing CRM or our own built tool, with consistent follow-up, documented pipeline stages, and regular reporting. CRMs in use: HubSpot, Salesforce, Pipedrive, Monday.
Conference and event representation
Face-to-face relationships remain the fastest way to build trust in the life sciences services market. CPHI, BIO, DCAT Week, ASCO, ASMO, and other sector events are key touchpoints. Corstrate can represent your company at these events, run pre-event outreach, and follow up on the meetings generated.
Reporting and market feedback
Weekly and monthly pipeline reports and market feedback so you understand what is moving, what is stalled, and what the competitive landscape looks like in your target accounts.
Buying Signals in Life Sciences BD
Buying signals are indicators that a prospect company is about to increase its outsourcing activity. In life sciences, these signals are specific and require sector knowledge to interpret correctly.
For a CRO or CDMO, relevant buying signals include:
-
A biotech announces a Series B or C funding round focused on clinical development
-
A pharma sponsor registers a new Phase II or III trial on clinicaltrials.gov
-
A sponsor hires a VP of Clinical Operations or a Head of CMC, indicating scale-up
-
A company expands its therapeutic pipeline into a new indication that requires capabilities they do not have in-house
-
A sponsor's existing CRO or CDMO relationship ends (visible through LinkedIn, regulatory filings, or conference conversations)
Identifying these signals consistently, and reaching out at the right moment with a relevant message, is what produces qualified meetings rather than ignored cold emails.
Buying signals for CROs and CDMOs include new clinical trial registrations, biotech funding rounds, and sponsor hiring patterns that indicate expanding outsourcing needs. Acting on these signals within days of their publication, with a message that demonstrates sector understanding, produces response rates that generic outreach cannot match.
Why Life Sciences BD Requires Sector-Specific Expertise
Selling CRO or CDMO services is not like selling SaaS. Your prospects are clinical operations directors, CMC heads, and procurement teams who evaluate suppliers on regulatory compliance, quality systems, and technical depth. A BD conversation that does not demonstrate familiarity with GCP requirements, RFP processes, and audit readiness signals will not get past the first meeting.
A fractional BD consultant for CROs and CDMOs should understand GCP requirements, RFP processes, and the 6-to-18-month sales cycles typical of the life sciences services market. Without this background, the outreach sounds like it could have been sent to any industry. With it, the message speaks directly to the priorities of the person reading it.
This is the gap that generic marketing agencies and lead generation tools cannot fill.
About Imen Jelassi, Your Fractional BD Partner
Imen Jelassi, PharmD, has spent 17 years in pharma, 14 years in business development for life sciences service providers, including CROs, CDMOs, and regulatory consultancies.
Her background spans both sides of the clinical research process: she started as a Clinical Research Associate, monitoring Phase III and IV trials in various therapeutic areas. She knows what CRO operations look like from the inside, which means she speaks the same technical language as the people she is prospecting.
Since 2012, Imen has worked exclusively in BD for life sciences service companies, covering CROs, CDMOs, regulatory consultancies, PV firms, data management and biostatistics providers, imaging for clinical trials, medical writing companies, and early-stage biotechs.
Her credentials:
-
PharmD, (2008)
-
MSc Health Marketing, Négociation et Ventes, Université Pierre et Marie Curie Paris (2015)
-
HubSpot Certified
-
GCP and GMP trained
-
CRMs: HubSpot, Salesforce, Pipedrive, Monday
Her international exposure covers the US, UK, France, Germany, Switzerland, Belgium, the Netherlands, Africa, Asia, and MENA.
Corstrate was founded in 2019 as a BD consultancy dedicated exclusively to small life sciences service providers.
Fractional BD for the US, UK and European Life Sciences Market
United States
The US market is the largest single market for CRO and CDMO services. FDA-regulated environments, a large base of biotech sponsors, and a direct commercial culture make it a priority for service providers looking to scale. Entry requires understanding the FDA regulatory framework, US procurement norms, and which conferences and networks are relevant to your specific service category.
United Kingdom
The UK market has its own regulatory environment post-Brexit, governed by the MHRA alongside ongoing EMA alignment. The CRO and CDMO ecosystem in the UK is dense, with established players and a culture of long-term partnership rather than transactional buying. Market entry here rewards consistency and relationship depth.
Europe
Key European markets for life sciences services include Germany, the Netherlands, Belgium, France, and Switzerland, each with its own cluster of CRO and CDMO activity. Germany and Switzerland have a high concentration of large pharma clients with sophisticated procurement processes. The Netherlands and Belgium are home to several mid-size biotechs actively expanding their pipelines.
Covering multiple geographies simultaneously, rather than sequentially, is an advantage for CROs and CDMOs that want to reduce dependency on a single market.
Frequently Asked Questions
How does fractional BD differ from hiring a full-time BD director?
A full-time BD director is a fixed cost of $150,000 to $200,000+ per year, with benefits, equity, and a ramp-up period before they produce results. A fractional BD consultant brings the same level of expertise with a variable cost structure, no equity dilution, and no recruitment timeline. You pay for the work, not the headcount.
When should a small CRO or CDMO consider outsourcing their business development?
If your pipeline is inconsistent, if you have no dedicated BD person, or if you are trying to enter a new geography without a local network, fractional BD is the fastest way to get structured, expert-led commercial activity in place without a full-time hire.
What types of life sciences service providers benefit from fractional BD?
CROs and CDMOs are the primary target, but the model works for any life sciences service provider selling to pharma, biotech, or medtech sponsors: regulatory consultancies, PV companies, data management and biostats firms, medical writing providers, and early-stage biotechs with a service offering.
How does working with a fractional BD consultant work in practice?
The engagement starts with a strategy session to define your ICP, value proposition, and target geography. From there, Corstrate runs structured outreach on a defined cadence, manages your pipeline, and delivers monthly reporting. The level of involvement is adapted to your needs, from strategic advisory to full BD execution.
What are buying signals and how are they used in life sciences BD?
Buying signals are publicly available indicators that a prospect company is about to increase its outsourcing activity: a new clinical trial registration, a funding round, a senior clinical hire, or a pipeline expansion into a new therapeutic area. Identifying and acting on these signals at the right moment, with a technically credible message, is what produces qualified conversations rather than ignored outreach.
Ready to Build a Consistent BD Pipeline?
If you are running a CRO, CDMO, or life sciences service company and your pipeline is inconsistent, we should talk. Book a free BD consultation to discuss your target markets, your current BD approach, and what a fractional model could look like for your business.
Not sure yet? See how Corstrate approaches lead generation for life sciences.
Explore real outcomes from our outsourced business development programs in our client case studies.
Corstrate is a boutique consultancy specializing in fractional and outbound business development for CROs, CDMOs and life sciences service providers.
Related reading
Senior BD expertise without a full-time hire.
Fractional Business Development for Life Sciences
A smarter growth model for 2026, senior BD expertise on demand.
Inbound and Outbound Sales: Why You Need Both
How inbound and outbound work together to build a strong life sciences pipeline.
Pipeline Optimization: Building a Predictable Revenue Engine
The complete guide to a repeatable life sciences sales pipeline.